No title
Despite advances in understanding the mechanisms, risk factors and treatment strategies for Alzheimer’s disease (AD), no approved therapies exist to prevent or delay onset in at-risk individuals or those with elevated biomarkers who do not yet show symptoms. Multiple candidate interventions are now being evaluated in clinical trials in these settings, raising key questions around which populations
